I-FOS TABLETS

Indications

• Osteoporosis in postmenopausal women
• Prevention of osteoporosis in high-risk postmenopausal women

Dosage

Adults: For osteoporosis treatment, the usual adult dose is 150 mg orally once a month.

Mechanism of action

Ibandronate binds to hydroxyapatite in bone, where it is taken up by osteoclasts during bone resorption. This process involves local acidification that releases ibandronate, which is then internalized by osteoclasts through fluid-phase endocytosis. Once inside, it disrupts the function of osteoclasts by interfering with the mevalonate pathway and inducing apoptosis through mechanisms involving caspase-3 activation. This ultimately leads to reduced bone resorption and increased bone density.

Pharmacodynamics

Ibandronate is used to treat and prevent osteoporosis in postmenopausal women, with a long duration of action and a wide therapeutic index. Adverse effects may include upper gastrointestinal reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical femoral fractures, and renal impairment. Its prolonged half-life, which can extend up to 157 hours, allows for less frequent dosing.

Pharmacokinetics

After oral administration, ibandronate is poorly absorbed, with bioavailability significantly reduced by food and certain medications (such as antacids and calcium supplements). It is extensively distributed in the bone and has a long elimination half-life due to its binding properties. The drug is primarily excreted unchanged through the kidneys. Renal impairment can affect its clearance, necessitating dose adjustments in patients with compromised kidney function.

Adverse effects

• gastrointestinal irritation
• hypocalcemia
• musculoskeletal pain
• osteonecrosis of the jaw
• atypical fractures of the femur
• severe renal impairment

Interactions

• oral antacids (decreases absorption)
• aspirin (increases risk of gastrointestinal irritation)
• NSAIDs (increases risk of gastrointestinal irritation)
• oral calcium salts (decreases absorption)
• oral iron (decreases absorption)
• oral magnesium (decreases absorption)
• oral zinc (decreases absorption)

Precautions

• Monitor calcium levels
• Assess renal function prior to initiation
• Evaluate for history of gastrointestinal disorders

Pregnancy

Ibandronate is not recommended during pregnancy due to potential risks to the fetus.

Breast-feeding

Caution is advised as the effects on breastfed infants are unknown.

Storage

Store at room temperature, away from moisture and light.

Formulations

• tablets
• injectable solution

Mechanism of action

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. ibandronate also activated caspase-3 which contribute to apoptosis.

Pharmacodynamics

Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women. The therapeutic index is wide as overdoses are not especially toxic, and the duration of action is long as the half life can be up to 157 hours. Patients should be counselled regarding the risk of upper GI adverse reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures of the femur, and severe renal impairment.